About Coxsackievirus and adenovirus receptor
Coxsackievirus and adenovirus receptor (CXADR) is a protein
from Homo sapiens identified by UniProt accession
P78310, 365 residues long.
MolForge cross-references it against 0 known binders and
234 disease associations.
Target properties
| Protein name | Coxsackievirus and adenovirus receptor |
|---|
| UniProt accession | P78310 |
|---|
| Gene | CXADR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 365 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (234)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.48
- FEV/FVC ratio · score 0.44
- neurodegenerative disease · score 0.37
- leukocyte count · score 0.31
- monocyte percentage of leukocytes · score 0.30
- aspartate aminotransferase measurement · score 0.29
- diet measurement · score 0.28
- hypertension · score 0.28
- glioblastoma multiforme · score 0.19
- neurofibrillary tangles measurement · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P78310-F1 | alphafold | PREDICTED | 79.30 | — |
Amino-acid sequence (365 residues)
MALLLCFVLL CGVVDFARSL SITTPEEMIE KAKGETAYLP CKFTLSPEDQ GPLDIEWLIS PADNQKVDQV IILYSGDKIY DDYYPDLKGR VHFTSNDLKS GDASINVTNL QLSDIGTYQC KVKKAPGVAN KKIHLVVLVK PSGARCYVDG SEEIGSDFKI KCEPKEGSLP LQYEWQKLSD SQKMPTSWLA EMTSSVISVK NASSEYSGTY SCTVRNRVGS DQCLLRLNVV PPSNKAGLIA GAIIGTLLAL ALIGLIIFCC RKKRREEKYE KEVHHDIRED VPPPKSRTST ARSYIGSNHS SLGSMSPSNM EGYSKTQYNQ VPSEDFERTP QSPTLPPAKV AAPNLSRMGA IPVMIPAQSK DGSIV
Explore Coxsackievirus and adenovirus receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets